Pneumococcal Vaccines

Arthur Reingold, MD
Pneumococcal Vaccines Work Group Chair
Advisory Committee on Immunization Practices
October 26, 2017
Pneumococcal Vaccines Work Group

• ACIP members
  – Arthur Reingold (Chair)
  – Nancy Bennett
  – Allison Kempe
  – Paul Hunter
  – Grace Lee

• Ex officio members
  – Tina Mongeau (FDA)
  – Lucia Lee (FDA)

• CDC lead
  – Tamara Pilishvili (NCIRD)

• Liaison representatives and consultants
  – Lorry Rubin (AAP)
  – Carol Baker (AAP)
  – Mark Sawyer (AAP/CIOD)
  – Rick Zimmerman (AAFP)
  – Chris Lupold (AAFP)
  – Sandra Fryhofer (ACP)
  – Jane Zucker (AIM)
  – William Schaffner (NFID)
  – Monica Farley (DVA)
  – Jeffrey Duchin (U. of Washington)
  – Keith Klugman (Gates Foundation)
  – Kathy Neuzil (IDSA)
Pneumococcal Vaccines Work Group: Terms of Reference

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines

- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence

- Revise or update recommendations for pneumococcal vaccine use, as needed
PCV13 recommendations over time

- PCV13 in children
- PCV13 for adults ≥19 years with immunocompromising conditions
- PCV13 in adults ≥65 years old
ACIP August 2014: PCV13 recommended for adults 65 years and older

- Work Group and ACIP Conclusions
  - Short term: recommendation for universal PCV13 use is warranted
  - Long term: continued herd effects may limit the utility of a universal recommendation
    - Magnitude of indirect effects unknown
    - Uncertainty around the burden of vaccine preventable non-bacteremic pneumonia
  - Recommendation for re-evaluation and revision as needed of routine PCV13 use among adults 65 years and older in 2018
Re-evaluation of PCV13 for adults 65 years and older recommendation

• Monitor pneumococcal disease and vaccine impact in the target population of adults 65 years and older

• Monitor indirect vaccine effects on pneumococcal disease trends among PCV13-naïve adults (19-64 years old without PCV13 indications)

• Routinely update ACIP on direct and indirect effects and pneumococcal disease trends among adults leading up to 2018 discussions
October 2016 ACIP Meeting

- Updated on changes in invasive pneumococcal disease following PCV13 introduction in children
  - Indirect (herd) effects among adults
  - No data on direct effects of PCV13 use among adults

- Presented outline of research agenda to inform potential policy change in 2018
Today’s Pneumococcal Vaccines Session

Outline

• Pneumococcal colonization studies
  – Among children <5 years of age
    • Stepy Thomas, GA Emerging Infections Program, VA Medical Center
  – Among adults ≥65 years old
    • Fernanda Lessa, NCIRD

• Changes in invasive pneumococcal disease in children, adults, and adults living with HIV
  – Almea Matanock, NCIRD

• Progress of research to inform potential policy reconsideration in 2018 for PCV13 use among adults
  – Tamara Pilishvili, NCIRD
Discussion Questions for Today’s Pneumococcal Vaccines Session

• Is the proposed research agenda appropriate to help determine if potential policy change is needed in 2018?

• What additional information will the committee need to help determine in 2018 whether continued PCV13 use in adults 65 years and older is warranted?